Cantor Fitzgerald reiterated its Overweight rating on AbbVie shares. The firm cited positive clinical data for zumilokibart, an anti-IL-13 treatment for atopic dermatitis acquired through the Apogee deal.
Zumilokibart demonstrated a 121% reversal in lesional gene expression. This result outperformed the 98% reversal rate achieved by its primary competitor, Dupixent.
Cantor Fitzgerald noted the drug offers superior efficacy and potential for more convenient dosing. This development strengthens AbbVie’s immunology franchise and validates its strategic acquisition strategy for future growth.